Nouscom Raises €120M to Advance Cancer Prevention Vaccine - European Biotechnology Magazine
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.5 Articles
5 Articles
Switzerland's Nouscom bags €120 million to bring innovative cancer immunotherapy closer to clinical trials
Basel-based Nouscom, a clinical-stage, cancer interception focused BioTech developing next-generation immunotherapies, today announced the closing of an oversubscribed €120 million ($135 million) Series D financing to fund the advancement of an investigational off-the-shelf neoantigen-based cancer immunotherapy. The round was co-led by M Ventures and Revelation Partners alongside new investors Angelini Ventures, the EIB, and Neva […]
(Teleborsa) - Neva SGR, venture capital company of the Intesa Sanpaolo Group, has invested with its Neva II Fund in Nouscom, a biotechnology company specializing in the interception of...
The round series D will be used to develop NOUS-209, the experimental immunotherapy that aims to block cancer before it develops in people with Lynch syndrome.New investors: Angelini Industries through Angelini Investments, EIB through Aurea and Neva SGR (Intesa Sanpaolo). Biotech is based in Basel and research activities in Rome Article A Nouscom 120 million to intercept cancer: Angelini Industries, EIB and Neva enter comes from Economyup.
Nouscom raises €120M to advance cancer prevention vaccine - European Biotechnology Magazine
Swiss biotech Nouscom has raised €120 million in an oversubscribed Series D financing to advance NOUS-209, an experimental cancer vaccine designed to prevent tumors in people with Lynch syndrome, into a global registration-enabling clinical trial. Alongside the financing, the company has released new long-term clinical data showing encouraging signs of cancer prevention.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
